Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), announced that its wholly owned subsidiary Aptorum Therapeutics Limited (“ATL”) has entered into a non-binding Letter of Intent and Term Sheet (“Term Sheet”) to merge (“Transaction”) its 100% subsidiary, Paths Innovation Limited and its underlying business (collectively “PathsDx Group”) with Universal Sequencing Technology Corporation (“UST”), a San Diego and Boston based US company dedicated to the development and commercialization of advanced proprietary DNA sequencing technologies. Paths Innovation Limited currently holds, through its majority owned subsidiary Paths Diagnostics Pte. Limited, the PathsDx technology – a liquid biopsy NGS based technology for the diagnostics of infectious diseases.
Read the full article: Aptorum Therapeutics Limited Enters into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited //
Source: https://www.businesswire.com/news/home/20230501005066/en/Aptorum-Therapeutics-Limited-Enters-Into-Letter-of-Intent-and-Term-Sheet-with-Universal-Sequencing-Technology-Corporation-to-Merge-with-Aptorum-Group%E2%80%99s-Subsidiary-Paths-Innovations-Limited